Oncology Move over CAR-T: The potential of NK cells in cell therapy The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren't the only option for cell th
News FDA sets May date for verdict on ADC’s lymphoma drug Lonca ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a priority review of lead drug Lonca for diffuse large B-cell lymphoma (DLBCL), an aggressi
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.